The FDA accepts a biologics license application (BLA) for a first-of-its-kind optogenetic gene therapy for RP; a software upgrade from Heru combines several pretesting assessments into a single guided workflow; and a new FDA-approved overnight orthokeratology lens is launched in the US.

Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first patient in a global phase 3 trial of an investigational gene therapy for geographic atrophy (GA).

Learn more about your ad choices. Visit megaphone.fm/adchoices

Eyepoint Pharmaceuticals releases key phase 3 data for its wet AMD drug Duravyu; Zeiss receives FDA clearance for a cloud- and browser-based data management solution; and the FDA expands Sight Sciences’ indications for the TearCare System for the treatment of MGD.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Tarsus Pharmaceuticals enters into a definitive agreement to acquire Alkeus Pharmaceuticals; Harrow acquires dry eye disease nasal spray Tyrvaya from Viatris; and Italy-based Alfasigma enters into a share purchase agreement with Sever Life Sciences to acquire 100% of Nordic Pharma and its subsidiaries.

Learn more about your ad choices. Visit megaphone.fm/adchoices

An interchangeable biosimilar to Eylea is launched in the US; patient enrollment is completed in two global phase 3 clinical trials evaluating Duravyu for diabetic macular edema; and Topcon receives CE mark for a fully automated ultra-widefield retinal slit scanner.

Learn more about your ad choices. Visit megaphone.fm/adchoices

The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt.

Learn more about your ad choices. Visit megaphone.fm/adchoices

A retinal implant system allowing patients with GA to regain some functional central vision vison is approved in Europe; Bausch + Lomb launches a new preloaded IOL delivery system in the US; and we review recent advancements and milestones in the development of novel ophthalmic treatments.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Tarsus acquires the maker of an investigational ocular antiseptic; Alcon and RxSight partner to jointly develop adjustable PCIOLs; and the FDA will hold a meeting to discuss Sydnexis’ investigational low-dose atropine therapy for myopia.

Learn more about your ad choices. Visit megaphone.fm/adchoices

An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated laser-indirect-ophthalmoscope.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Ocular Therapeutix provides a key update on its NDA plans for wet AMD drug candidate Axpaxli; Thea US launches a first-of-its-kind eye gel for glaucoma; and there were several recent milestones reached in the clinical development of novel drugs for a variety of ocular conditions.

Learn more about your ad choices. Visit megaphone.fm/adchoices